Top 10 paper in #yesCCT by @ToddVillinesMD
1st paper
📝 Italian COVID 19 registry
N=1625
📝 Increasing #CAC associated with worse covid 19 outcomes of hospital death, MI and CVA
#YesCCT
1st paper
📝 Italian COVID 19 registry
N=1625
📝 Increasing #CAC associated with worse covid 19 outcomes of hospital death, MI and CVA
#YesCCT
2nd paper #Top10 papers #yesCCT
#SCCT2021
danish heart registry
📝 Plaque burden, not stenosis the main predictor of MACE
📝 patients with a comparable calcified atherosclerosis burden generally carry a similar risk for CVD events
jacc.org/doi/abs/10.101…
#SCCT2021
danish heart registry
📝 Plaque burden, not stenosis the main predictor of MACE
📝 patients with a comparable calcified atherosclerosis burden generally carry a similar risk for CVD events
jacc.org/doi/abs/10.101…
3rd paper #Top10 papers #yesCCT
#SCCT2021
CREDENCE trial
📝 Stress MPI vs #yesCCT for diagnosis of coronary physiology
📝 #yesCCT superior to stress MPI in the diagnosis of invasive FFR
jamanetwork.com/journals/jamac…
@lesleejshaw @RonBlankstein @AChoiHeart @ghoshhajra
#SCCT2021
CREDENCE trial
📝 Stress MPI vs #yesCCT for diagnosis of coronary physiology
📝 #yesCCT superior to stress MPI in the diagnosis of invasive FFR
jamanetwork.com/journals/jamac…
@lesleejshaw @RonBlankstein @AChoiHeart @ghoshhajra
4th paper of #Top10 papers #yesCCT
#SCCT2021
Machine learning - plaque assessment
📝 6 features,
MLA,
% atheroma volume,
fibrofatty/necrotic core volume, plaque volume,
Prox LAD lesion,
remodeling index,
define ischemia & prognosticate.
sciencedirect.com/science/articl…
#SCCT2021
Machine learning - plaque assessment
📝 6 features,
MLA,
% atheroma volume,
fibrofatty/necrotic core volume, plaque volume,
Prox LAD lesion,
remodeling index,
define ischemia & prognosticate.
sciencedirect.com/science/articl…
5th paper of #Top10 papers #yesCCT
#SCCT2021
Evaporate trial
📝 Icosapent ethyl demonstrated significant regression of low attenuation plaque volume on #yesCCT compared with placebo over 18 months.
academic.oup.com/eurheartj/arti…
@mirvatalasnag @DBelardoMD @JamalRanaMD
#SCCT2021
Evaporate trial
📝 Icosapent ethyl demonstrated significant regression of low attenuation plaque volume on #yesCCT compared with placebo over 18 months.
academic.oup.com/eurheartj/arti…
@mirvatalasnag @DBelardoMD @JamalRanaMD
6th paper of top 10 #yesCCT #SCCT2021
#Ischemia trial
CCTA before randomization in ISCHEMIA -> high concordance with cath results for identification of patients with angiographically significant disease without LM disease.
jacc.org/doi/pdf/10.101…
#Ischemia trial
CCTA before randomization in ISCHEMIA -> high concordance with cath results for identification of patients with angiographically significant disease without LM disease.
jacc.org/doi/pdf/10.101…
7th paper of top 10 papers
#SCCT2021
📝 Pre-procedural #yesCCT for CTO ->⬆️ success rates with ⬇️ periprocedural complications ie coronary perforations/ periprocedural MI than angiography guidance.
📝 ⬆️ success rates in pts with ⬆️ high J-CTO score
jacc.org/doi/abs/10.101…
#SCCT2021
📝 Pre-procedural #yesCCT for CTO ->⬆️ success rates with ⬇️ periprocedural complications ie coronary perforations/ periprocedural MI than angiography guidance.
📝 ⬆️ success rates in pts with ⬆️ high J-CTO score
jacc.org/doi/abs/10.101…
8th paper of top 10 papers #SCCT2021 @ToddVillinesMD
📝 Contrast-enhanced #yesCCT of AV calcific & non-calcific volumes correlates with AS severity and preferable to non-contrast CT when fibrosis is a significant contributor to valve obstruction.
heart.bmj.com/content/early/…
📝 Contrast-enhanced #yesCCT of AV calcific & non-calcific volumes correlates with AS severity and preferable to non-contrast CT when fibrosis is a significant contributor to valve obstruction.
heart.bmj.com/content/early/…
9th paper top 10 paper at #SCCT2021
📝 post-TAVR #yesCCT substantially downgraded the prevalence of P-PM compared to TTE
📝 post-TAVR #yesCCT identifies subset of patients with clinically relevant P-PM which associated with outcomes.
journalofcardiovascularct.com/article/S1934-…
📝 post-TAVR #yesCCT substantially downgraded the prevalence of P-PM compared to TTE
📝 post-TAVR #yesCCT identifies subset of patients with clinically relevant P-PM which associated with outcomes.
journalofcardiovascularct.com/article/S1934-…
Last paper top 10 paper at #SCCT2021
MESA participants, Baseline CAC=0, Follow up at 10 years
->15% progressed to CAC >10 in 5-8 years
-> 10-year progression to CAC >100 = rare.
-> consider rescanning in 3 to 7 years
sciencedirect.com/science/articl…
MESA participants, Baseline CAC=0, Follow up at 10 years
->15% progressed to CAC >10 in 5-8 years
-> 10-year progression to CAC >100 = rare.
-> consider rescanning in 3 to 7 years
sciencedirect.com/science/articl…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
